Gordian Capital Singapore Pte Ltd Lowers Holdings in Eli Lilly and Company (NYSE:LLY)

Gordian Capital Singapore Pte Ltd decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 56.9% in the second quarter, Holdings Channel reports. The firm owned 409 shares of the company’s stock after selling 541 shares during the quarter. Gordian Capital Singapore Pte Ltd’s holdings in Eli Lilly and Company were worth $370,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Strategic Investment Solutions Inc. IL bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth $565,000. RiverFront Investment Group LLC bought a new stake in Eli Lilly and Company during the second quarter valued at approximately $256,000. Sycomore Asset Management grew its position in Eli Lilly and Company by 206.4% during the second quarter. Sycomore Asset Management now owns 39,013 shares of the company’s stock valued at $35,161,000 after buying an additional 26,282 shares during the period. Heritage Oak Wealth Advisors LLC bought a new position in Eli Lilly and Company in the second quarter worth approximately $371,000. Finally, New Wave Wealth Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 2nd quarter worth $1,217,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the transaction, the insider now owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold 355,962 shares of company stock worth $331,267,535 over the last quarter. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Price Performance

NYSE LLY opened at $884.55 on Wednesday. The company has a 50 day simple moving average of $896.62 and a 200-day simple moving average of $845.90. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The firm has a market capitalization of $840.68 billion, a price-to-earnings ratio of 130.27, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Equities research analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on LLY. Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Bank of America lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, September 16th. Barclays upped their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Finally, Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.